|
Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial. |
|
|
Consulting or Advisory Role - Merck Serono |
Research Funding - Merck Serono (Inst) |
|
|
Honoraria - Amgen; Merck; Roche |
Consulting or Advisory Role - Amgen; Merck; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Lilly; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical |
Consulting or Advisory Role - Bayer; Lilly; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical |
Research Funding - Novartis |
|
|
Travel, Accommodations, Expenses - Janssen; Merck; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Lilly; Merck Serono; Roche; Sanofi |
Research Funding - AstraZeneca (Inst); Merck Serono (Inst) |
|
|
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck Serono; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Honsha |
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst) |
|
|
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst) |
|
|
Honoraria - Amgen; Celgene; Lilly; Merck Serono; Roche; Sanofi |
Travel, Accommodations, Expenses - Amgen; Celgene; Merck Serono; Roche |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
Travel, Accommodations, Expenses - EMD Serono; Medivation |
Other Relationship - The Oncologist, Editor |